Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Cryotherapy for Bronchoscopic Management of Central Airway Obstruction: Clinical Experience at Assiut University Hospital.

16. November 2026 aktualisiert von: Ebtesam Adel Hammad Askar, Assiut University

The aim of this study is to evaluate the clinical efficacy of therapeutic bronchoscopic cryotherapy for management of central airway obstruction (CAO).

Studienübersicht

Detaillierte Beschreibung

Introduction:

Central airway obstruction (CAO) is defined as significant narrowing of the trachea, main stem bronchi or the bronchus intermedius, and occurs in a wide variety of airway disorders, including endobronchial tumors, post-intubation and post-tracheostomy stenosis, post-infectious stenosis, granulation tissue, tracheomalacia, and foreign body obstruction . It is associated with a poor prognosis and impaired quality of life, even when the underlying cause is benign.

Therapeutic bronchoscopy can improve symptoms, quality of life, and survival in patients with CAO, and the current American College of Chest Physicians guideline supports a multimodality approach that includes tissue debridement, ablation, dilation, and stent placement according to the underlying disease . Recent evidence shows substantial improvements in breathlessness and quality of life after therapeutic airway interventions, with a low complication rate in a large long-term series.

Bronchoscopic cryotherapy is a pragmatic modality for recanalization of CAO that can be delivered through a flexible bronchoscope under moderate sedation, achieving more than partial airway patency in about 90% of sessions in an 11-year single-center cohort, although bleeding remains the main concern [7]. Its usefulness has also been shown in tumor-like endobronchial tuberculosis and, with the spray technique, in a prospective registry of central airway diseases . In Egypt, a single-center study reported that cryotherapy was safe and improved clinical scores, pulmonary function, and quality of life in patients with CAO of different etiologies . Evidence regarding bronchoscopic cryotherapy for CAO remains limited in our region despite its increasing clinical utilization. This study aims to assess the feasibility, safety, and clinical outcomes of bronchoscopic cryotherapy for CAO within the constraints of a resource-limited healthcare environment and evaluating our institutional experience at Assiut University Hospital.

  • The aim of this study is to evaluate the clinical efficacy of therapeutic bronchoscopic cryotherapy for management of central airway obstruction (CAO).

  • Type of the study: Prospective Interventional Study.

  • Study Group: The study will include patients diagnosed with central airway obstruction (CAO) and fit for bronchoscopy.

  • Study Setting: Respiratory bronchoscopy unit, Assuit University Hospital. Study subjects: All adult patients diagnosed with central airway obstruction(CAO) and fit for bronchoscopic intervention will be eligible.

    a. Inclusion criteria:

    • Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy
    • b. Exclusion criteria:
    • Patients with coagulopathy (INR > 1.5).
    • Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
    • Severe pulmonary hypertension (PASP > 55 mmHg).
    • Hemodynamic instability.
    • Lung collapse > 2 months duration. c.Sample size calculation:

The sample size was calculated using Epi Info™️ version 7 software based on the following assumptions:

The primary outcome variable was the successful airway recanalization rate. Based on a previous study by Hussein et al. (2026), the overall successful recanalization rate (complete and partial) was 96%. Assuming an expected proportion of 96%, a confidence level of 90%, and a confidence limit (margin of error) of 5%, the minimum required sample size was estimated to be 42.

  • Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …):

Baseline Evaluation

Prior to the intervention, all candidates will undergo:

  • Clinical Assessment: Detailed history taking, physical examination, and dyspnea assessment using the modified Medical Research Council (mMRC) scale, while cough and hemoptysis were evaluated using the Walsh cough score and the Morice hemoptysis severity score, respectively.

  • Laboratory Tests: CBC, liver/kidney functions, coagulation profile, fasting blood glucose, and Arterial Blood Gases (ABG)

  • Radiological Imaging: Plain Chest X-ray (PA view) and CT chest to evaluate the site and extent of the obstruction.

  • Functional assessment : ABG and pulmonary function test pre and post procedure. Intervention Protocol (Therapeutic Bronchoscopy)

    1. General Preparation

  • Anesthesia: This procedure will be performed under local anesthesia .

  • Equipment: A flexible bronchoscope (e.g., Pentax EBK-3000) with a 3.2 mm working channel.

  • Pre-medication: Intramuscular atropine (0.5 mg) to reduce secretions and prevent vasovagal reflexes and nebulized lidocaine.

  • Mapping: Determination of the location and degree of obstruction according to the Freitag et al [8]. scheme.

    1. Specific Techniques

Bronchoscopic Cryotherapy (ERBOKRYO CA):

In a well-equipped room with monitoring of blood pressure ,heart rate ,respiratory rate and oxygen saturation.

  • Mechanism: Utilizing the Joule-Thompson effect, where high-pressure (60 bar) carbon dioxide as a cooling agent rapidly expands at the probe tip due to the difference with the atmospheric pressure, reducing the temperature to approximately - 78 °C [9].
  • Application: Procedures will be conducted under local aesthesia in one or two sessions, each lasting 30-60 min. The cryo¬probe will be inserted through the bronchoscope biopsy channel which is positioned approximately 10 mm above the lesion and the probe is in direct contact to the lesion. The lesion will be frozen for 20-60 s/cycle for three cycles to devascularize the tumor, after which the bronchoscope and cryoprobe will be removed together with adherent tissue.

IV. Follow-up Parameters

  • Immediate (Post-procedure): Chest X-ray within 2 hours to exclude pneumothorax.
  • Short-term: Monitoring for peri-procedural complications within the first 24 hours Complications were classified as minor (e.g., self-limited bleeding, transient hypoxemia, mild pneumomediastinum not requiring invasive intervention) or major (e.g., life-threatening bleeding, respiratory failure requiring ventilatory support, pneumothorax requiring chest tube insertion).This classification was conceptually aligned with the Common Terminology Criteria for Adverse Events (CTCAE) framework.
  • Bronchoscopic grading of bleeding severity; Grade 1: Bleeding requiring suctioning for less than 1 minute. Grade 2: Bleeding requiring suctioning for more than 1 minute, repeated wedging of the bronchoscope, or topical haemostatic agents.

Grade 3: Bleeding requiring selective intubation with an endotracheal tube or balloon/bronchial blocker for less than 20 minutes, or premature termination of the procedure.

Grade 4: Persistent selective intubation for more than 20 minutes, ICU admission, transfusion, bronchial artery embolisation, or resuscitation.

- Long-term: Patients will be followed for up to 3 months post-procedure, including:

  • Clinical evaluation ;

    - Quality of life (SF-36),symptoms(cough,dyspnea,hemoptysis).

  • Functional Evaluation ; ABG and spirometry.

  • Bronchoscopic evaluation (to check for re-obstruction)if clinically indicated.

  • Radiological evaluation (CT or Chest X-ray).

    • Research outcome measures:

      1. Primary (main):

Technical efficacy: Percentage of patients achieving successful airway recanalization following bronchoscopic cryotherapy, according to the Freitag et al & Hussein et al :

  1. Complete canalization: ≥90% restoration of airway lumen
  2. Partial canalization: 50-89% restoration.
  3. Failed canalization: <50% restoration or inability to proceed due to complications

b. Secondary (subsidiary):

  1. Symptomatic Improvement: Changes in dyspnea (mMRC scale),cough and hemoptysis score evaluated at short-term and at the 3-month follow-up.
  2. Safety Profile: incidence of minor and major peri-procedural complications within 24 hours, categorized using the Common Terminology Criteria for Adverse Events (CTCAE) framework.
  3. Long-term Airway Patency: Rate of re-obstruction and CAO-related re-hospitalization during the 3-month follow-up period.
  4. Overall Survival: Estimation of the 1-year overall survival (OS) rate post-intervention

Studientyp

Interventionell

Einschreibung (Geschätzt)

42

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Ebtesam Adel Hammad Askar, Assistant Lecturer
  • Telefonnummer: +2001012089691
  • E-Mail: ebtesam6569@gmail.com

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

• Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy.

Exclusion Criteria:

  • Patients with coagulopathy (INR > 1.5).
  • Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
  • Severe pulmonary hypertension (PASP > 55 mmHg).
  • Hemodynamic instability.
  • Lung collapse > 2 months duration

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: All adult patients diagnosed with CAO and fit for bronchoscopic intervention

Study subjects: All adult patients diagnosed with CAO and fit for bronchoscopic intervention will be eligible.

a. Inclusion criteria:

  • Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy
  • b. Exclusion criteria:
  • Patients with coagulopathy (INR > 1.5).
  • Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
  • Severe pulmonary hypertension (PASP > 55 mmHg).
  • Hemodynamic instability.
  • Lung collapse > 2 months duration.

Intervention Protocol (Therapeutic Bronchoscopy)

  1. General Preparation

    • Anesthesia: This procedure will be performed under local anesthesia .
    • Equipment: A flexible bronchoscope (e.g., Pentax EBK-3000) with a 3.2 mm working channel.
    • Pre-medication: Intramuscular atropine (0.5 mg) to reduce secretions and prevent vasovagal reflexes and nebulized lidocaine.
    • Mapping: Determination of the location and degree of obstruction according to the Freitag et al [8]. scheme.

3. Specific Techniques

Bronchoscopic Cryotherapy (ERBOKRYO CA):

In a well-equipped room with monitoring of blood pressure ,heart rate ,respiratory rate and oxygen saturation.

  • Mechanism: Utilizing the Joule-Thompson effect, where high-pressure (60 bar) carbon dioxide as a cooling agent rapidly expands at the probe tip due to the difference with the atmospheric pressure, reducing the temperature to approximately - 78 °C [9].
  • Application: Procedures will be conducted under local aesthesia

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
percentage of patients achieving central airway recanalization.
Zeitfenster: Follow up after 3 months

Successful airway recanalization following therapeutic bronchoscopic cryotherapy for central airway obstruction (CAO), defined according to the Freitag et al. and Hussein et al. criteria.

Follow up after 3 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Dyspnea Severity.
Zeitfenster: baseline and at 3 months follow up

Change from baseline in dyspnea evaluated using the modified Medical Research Council (mMRC) dyspnea scale (score range 0 to 4, where higher scores indicate worse dyspnea).

baseline and at 3 months follow up
Change in Cough Score
Zeitfenster: baseline and at 3 months follow up period

Change from baseline according to walsh cough score

baseline and at 3 months follow up period
Change in Hemoptysis Score
Zeitfenster: baseline and at 3 months follow up period

Change from baseline according to morice hemoptysis score

baseline and at 3 months follow up period
Incidence of Minor and Major Peri-procedural Complications
Zeitfenster: Within 24 hours post-procedure

Number of participants with treatment-related adverse events and complications, categorized by severity using the Common Terminology Criteria for Adverse Events (CTCAE) framework.

Within 24 hours post-procedure
Rate of Airway Re-obstruction and CAO-related Re-hospitalization
Zeitfenster: up to 3 months

Percentage of patients experiencing symptomatic airway re-obstruction or requiring re-hospitalization related to central airway obstruction (CAO).

up to 3 months
1-Year Overall Survival (OS) Rate
Zeitfenster: 1 year

Percentage of participants alive at 1 year following the bronchoscopic cryotherapy intervention.

1 year

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

10. November 2026

Primärer Abschluss (Geschätzt)

10. November 2027

Studienabschluss (Geschätzt)

10. November 2028

Studienanmeldedaten

Zuerst eingereicht

3. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

16. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • AssiutU-med-2026

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren